# What are peptides? Amino acid chains, drugs and gaps

> Peptides are short chains of amino acids. Some are hormones, dozens are approved drugs worldwide, and many sold as research peptides have no FDA approval.

Source page: https://peptioresearch.com/articles/what-are-peptides/
Publisher: Peptio Research. Educational summary of published research, not medical advice.
Last checked against its sources: 2026-10-13
Type: Explainer

A peptide is a short chain of amino acids. StatPearls, a medical reference, describes peptides as "short-chain biopolymers, typically consisting of 2 to 50 amino acid residues" [1]. A residue is one amino acid once it has been joined into a chain. The links between residues are amide bonds, called peptide bonds, formed when two amino acids join and release a molecule of water [1]. Proteins are built the same way. The difference is length, and where exactly length tips a peptide into a protein depends on which source you read.

## Where a peptide ends and a protein begins

StatPearls draws the line by counting residues. Chains of 20 to 50 amino acids "are designated polypeptides", and "chains exceeding 50 residues are generally considered proteins" [1].

A 2022 review of therapeutic peptides by Wang and colleagues uses a different yardstick, weight rather than count. It describes therapeutic peptides as "usually with molecular weights of 500-5000 Da" [2]. A dalton (Da) is the unit used for the mass of molecules. The same review calls insulin "a peptide with 51 amino acids" [2], one residue past the point at which StatPearls says chains are generally considered proteins.

So the two sources draw the line in different places and in different units, and both hedge it with "typically", "generally" or "usually". Neither says the boundary is arbitrary. The practical reading is that "peptide" and "protein" are conventions for describing length, and that a molecule near the boundary may be called either.

## Peptides the body makes

Many hormones are peptides. The Wang review lists "natural human hormones, including insulin, oxytocin, vasopressin" among the starting points for peptide drug research [2].

- **Insulin.** The US label for Humulin R, a human insulin product, states that "the primary activity of insulin, including HUMULIN R, is the regulation of glucose metabolism" [3].
- **Oxytocin.** The label for Pitocin, an oxytocin product, calls it "a nonapeptide found in pituitary extracts from mammals" [4]. A nonapeptide is a chain of nine amino acids. The label adds that "oxytocin and vasopressin differ in regard to only two of the eight amino acids" [4].
- **GLP-1.** Glucagon-like peptide-1 is, in the Wang review's words, "a 37-amino acid peptide that regulates insulin production and secretion" [2].

## Peptides as approved medicines

Counts of approved peptide drugs differ by source, year and scope, and none of the sources read for this page says exactly what it counted.

- A 2018 review by Lau and Dunn: "Over 60 peptide drugs are approved in the United States and other major markets." [5]
- A 2021 review by Muttenthaler and colleagues: "Since the introduction of insulin almost a century ago, more than 80 peptide drugs have reached the market." [6]
- The 2022 Wang review: "more than 80 peptide drugs worldwide", of which "33 non-insulin peptide drugs have been approved worldwide since 2000" [2].

Insulin is the oldest of these medicines that the sources discuss. The Wang review says it "was first isolated by Frederick Banting in 1921" and "was already available for patients with diabetes mellitus just a year after its first isolation" [2]. Insulin is now made differently. The Humulin R label says "insulin human is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli", and gives its molecular weight as 5.808 kDa [3].

Semaglutide, sold as Ozempic, is a more recent example. Its label calls it "a human GLP-1 receptor agonist", meaning it acts on the same receptor as the body's GLP-1, and states that it "is a GLP-1 analogue with 94% sequence homology to human GLP-1" [7]. "The peptide backbone is produced by yeast fermentation." [7]

## Why most peptide drugs are injected

The reason is pharmacology. The Wang review says peptides are "easily hydrolyzed by digestive enzymes in the stomach and intestine", so "most peptide drugs are thus administrated by injection" [2]. Hydrolysis here means digestive enzymes cut the peptide bonds. The review adds that peptides have "weak membrane permeability", and that they are "chemically and physically unstable, with a short half-life and fast elimination in vivo" [2]. Half-life is the time it takes for half of a substance to be cleared from the blood.

The Pitocin label shows how short that can be: "Oxytocin has a plasma half-life of about 1 to 6 minutes which is decreased in late pregnancy and during lactation." [4]

Much peptide drug design works against these limits. The Ozempic label gives semaglutide "an elimination half-life of approximately 1 week" [7].

Semaglutide also exists as a tablet, and its label shows how hard oral delivery is. The absolute bioavailability, the share of the dose that reaches the bloodstream, is "0.4% to 1% after oral administration" [8]. Even that depends on an added ingredient: semaglutide is "co-formulated with SNAC which facilitates the absorption of semaglutide", and "the absorption of semaglutide predominantly occurs in the stomach" [8].

> **Key point.**
> Being a peptide does not make a substance safe or effective. Insulin, oxytocin and semaglutide are approved as specific products, each with its own label. That approval does not extend to other peptides.

## Approved drugs and "research peptides"

Many peptides sold online as "research peptides" have no FDA approval. FDA keeps a page of bulk drug substances, meaning raw active ingredients, that "may present significant safety risks" when used by pharmacies to compound medicines. It says these substances "have been placed in category 2 under the interim policies" [9]. Peptides in that table include GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 [9]. A second table on the same page lists substances whose nominations were withdrawn. Its entry for BPC-157 says compounded drugs containing it "may pose risk for immunogenicity for certain routes of administration" [9], meaning a risk of provoking an immune response.

The approved peptides above have labels setting out what they are, how they behave in the body and what they are approved for. The category 2 peptides have no such label. What FDA has and has not done about them is covered in [Is the FDA banning peptides?](/articles/is-the-fda-banning-peptides/).

> **Limitation.**
> This page covers US labels and FDA documents only. Other jurisdictions were not researched.

## Sources

1. Forbes Kaprive J, Merheb E. Protein Structure and Function (StatPearls, NBK562260). StatPearls Publishing, NCBI Bookshelf. 2026. https://pubmed.ncbi.nlm.nih.gov/32965931/
2. Wang L et al. Therapeutic peptides: current applications and future directions.. Signal Transduction and Targeted Therapy. 2022. https://doi.org/10.1038/s41392-022-00904-4
3. HUMULIN R (insulin human) injection, solution. Prescribing Information (BLA 018780), DailyMed. U.S. National Library of Medicine, DailyMed. 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b519bd83-038c-4ec5-a231-a51ec5cc291f
4. PITOCIN (oxytocin) injection. Prescribing Information (NDA 018261), DailyMed. U.S. National Library of Medicine, DailyMed. 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dddcdcc3-cd4d-4573-98ac-9468bea23a8b
5. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions.. Bioorganic & Medicinal Chemistry. 2018. https://doi.org/10.1016/j.bmc.2017.06.052
6. Muttenthaler M et al. Trends in peptide drug discovery.. Nature Reviews Drug Discovery. 2021. https://doi.org/10.1038/s41573-020-00135-8
7. OZEMPIC (semaglutide) injection, solution. Prescribing Information, revised 5/2026, DailyMed. U.S. National Library of Medicine, DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
8. OZEMPIC (oral semaglutide) tablet / RYBELSUS (oral semaglutide) tablet. Prescribing Information, revised 1/2026, DailyMed. U.S. National Library of Medicine, DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
